Construction method and application of cellulose nanocrystal-based temperature-responsive drug release system

By grafting the cellulose II nanocrystals with thermosensitive polymer F124, a temperature-responsive Pickering emulsion system was constructed, which solved the problem that traditional drug release systems could not adjust the release rate, and achieved precise control and biocompatibility of the drug release rate. Suitable for treatment of a variety of diseases.

CN118994597APending Publication Date: 2024-11-22NANJING FORESTRY UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411016719.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Traditional drug release systems cannot intelligently adjust the drug release rate according to changes in ambient temperature, resulting in poor treatment effects or side effects, and the biocompatibility and temperature response sensitivity of the material are difficult to meet clinical needs.

Method used

Using cellulose II nanocrystals (CNC-II) as substrate, a temperature-responsive Pickering emulsion system is constructed through a specific chemically modified grafting thermosensitive polymer F124 to achieve rapid release of drugs at specific temperatures.

Benefits of technology

It realizes precise control of drug release rate, improves therapeutic effect, reduces side effects, and the biocompatibility and degradability of the material are suitable for biomedical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118994597A_ABST
    Figure CN118994597A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a temperature-responsive drug release system based on cellulose nanocrystals (CNC-II), which is characterized in that the CNC-II is endowed with temperature sensitivity by modifying the end group of the CNC-II through a temperature-sensitive polymer, so that quick response to environment temperature change is realized; and the prepared Pickering emulsion can realize the change from emulsion stabilization to emulsion breaking according to the environment temperature, so that the drug release can be accurately controlled. According to the system, microcrystalline cellulose is adopted as a raw material, CNC-II is prepared through the steps of mercerizing, sulfuric acid hydrolysis, terminal group oxidation, amination reaction and the like, and then the CNC-II is grafted with a carboxylation modified temperature-sensitive polymer F124 to form a nano material with temperature sensitivity. The Pickering emulsion constructed by using the material can release drugs when the body temperature of a human body slightly changes, and has high responsiveness, accurate drug control, good biocompatibility and wide medical application potential. The invention provides a novel intelligent drug delivery solution for cancer, infectious disease and chronic disease management and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug release, and in particular to a drug release system constructed by using temperature responsive materials, which can control the release rate of the drug according to the change of ambient temperature. Background Art

[0002] Traditional drug release systems usually do not have the ability to respond to changes in ambient temperature, resulting in uncontrollable drug release rates, which may affect the therapeutic effect or produce side effects. Therefore, it is of great significance to develop a system that can intelligently adjust the drug release rate according to temperature changes.

[0003] Temperature-responsive drug release system is a smart drug delivery technology that can sense changes in ambient temperature and adjust the drug release rate accordingly, thereby achieving more precise and effective treatment. This system shows great potential in a variety of application scenarios, especially in the treatment of diseases that require fine control of drug concentration, such as cancer chemotherapy, diabetes management, and local infection treatment.

[0004] The mechanism of action of temperature-responsive drug release systems is mainly based on temperature-sensitive materials, which undergo physical or chemical property changes at specific temperatures, such as phase transitions of polymers or changes in enzyme activity. When the ambient temperature reaches a certain threshold, the system can release the drug quickly, or slow down the release rate under temperature changes to adapt to treatment needs.

[0005] Currently, researchers have developed a variety of temperature-responsive materials, including polymer-based composites, liquid crystals, magnetic nanoparticles, etc. These materials have been widely studied and applied to the construction of drug carriers. However, despite certain progress, the research and application of temperature-responsive drug release systems still face some challenges and problems.

[0006] First, the biocompatibility and biodegradability of materials are key factors in the design of drug release systems. Some synthetic polymers may have biocompatibility issues, which limits their clinical application. Secondly, the sensitivity and accuracy of temperature response are also important considerations. In the complex in vivo environment, how to ensure that the material responds to temperature changes both sensitively and accurately is a technical challenge. In addition, the prediction and control of drug release kinetics require further research to ensure that the drug release pattern meets the requirements of the therapeutic window.

[0007] In addition, despite the progress made in laboratory research, many temperature-responsive materials still face challenges such as large-scale production, cost-effectiveness and regulatory approval when they are translated into clinical applications. In addition, research on the simulation of complex disease states and the long-term stability of drug release systems also needs to be further strengthened.

[0008] In conclusion, as a cutting-edge drug delivery technology, the temperature-responsive drug release system has huge application potential and market demand. Future research needs to focus on improving the biocompatibility of materials, optimizing temperature response performance, deepening drug release kinetics research, and promoting clinical transformation to achieve safer, more effective, and smarter drug delivery.

[0009] Cellulose Nanocrystals (CNCs)-based responsive drug release system is an emerging research direction in the field of nanomedicine. CNCs have attracted widespread attention due to their excellent biocompatibility, biodegradability and renewability. The molecular chains of CNC (denoted as CNC-II) with cellulose II crystal configuration are arranged in antiparallel, and cellulose II has reducing end groups at both ends of the fiber. This feature allows the derivatization reaction of the reducing end of CNC-II to be carried out at both ends, and because the particle morphology of CNC-II is elliptical, the steric hindrance may be smaller during the grafting reaction, and the chemical modification reactivity of its reducing end should be higher. Therefore, this patent is based on the preparation of a temperature-responsive nanocellulose temperature-responsive drug release system based on the modification of the thermosensitive polymer F124 at both reducing ends of CNC-II, and uses ibuprofen as a model to study its temperature-responsive drug release effect, which is expected to further expand the application scenarios of CNC-II. Summary of the invention

[0010] To solve this problem, the present invention uses a thermosensitive compound F124 and adopts a topological chemical strategy to graft it onto the reducing end group of CNC-II to prepare a CNC-II with temperature responsive properties. The prepared thermosensitive CNC-II has sensitive temperature responsive performance, is suitable for human body temperature, can release drugs quickly and accurately, and has a wide range of application value. It is characterized in that the method comprises the following steps:

[0011] 1. A method for constructing a temperature-responsive drug release system, characterized in that the method comprises the following steps:

[0012] S1 raw material: microcrystalline cellulose, cotton linters, bleached pulp and other cellulose raw materials are used as the base material, and a thermosensitive polymer is used as the modification auxiliary agent; preferably, the cellulose raw material of S1 is microcrystalline cellulose, and the S1 thermosensitive modification agent is commercial polyether F124 (CAS: 9003-11-6), which is a block copolymer of propylene oxide and ethylene oxide, with a molecular weight Mn of 2090-2360;

[0013] S2 crystal conversion. 17.5wt.% NaOH solution is added to the microcrystalline cellulose to ensure complete conversion of the cellulose, and then the alkaline solution is removed by decanting the supernatant and vacuum filtration until the pH value of the suspension is neutral, and finally the mercerized cellulose raw material A1 is freeze-dried for subsequent use; preferably, the solid / liquid weight ratio of S2 is 1:20 and soaked for 24 hours to ensure complete conversion of the cellulose;

[0014] Preparation of S3 cellulose II nanocrystals (CNC-II): hydrolyze A1 in S2 in a 64% (w / v) H2SO4 solution, then centrifuge to remove the acid solution, and use dialysis to remove residual acid from the centrifuged cellulose nanocrystals; preferably, the solid / liquid weight ratio of the S3 hydrolysis is 1:100, the temperature is 45°C, and the time is 15 min;

[0015] S4 high-pressure homogenization: The hydrolyzed and dialyzed cellulose nanocrystals are treated with a high-pressure homogenizer to obtain relatively uniform cellulose II nanocrystals (CNC-II) A2; preferably, the concentration of the S4 high-pressure homogenization is 0.1wt.%, the pressure is 400bar, and the number of homogenizations is 15-20 times;

[0016] S5 concentration: Subsequently, the homogenized A2 suspension is rotary evaporated to a specific concentration for subsequent use;

[0017] S6 substrate end group oxidation: NaClO2 is added to the CNC-II suspension described in S5, and acetic acid is added dropwise to adjust the pH, and the oxidation reaction is carried out by continuous stirring. After the reaction time is reached, an alkali solution is added to terminate the reaction, and the sample is transferred to a dialysis bag and dialyzed against water until the conductivity is constant to obtain a purified reducing end oxidation sample A3;

[0018] Preferably, the reaction conditions of S6 are: CNC-II concentration 1wt.%, and CNC-II:NaClO2 weight ratio 1:3.78; the pH of the reaction system is adjusted to 3.5, the reaction time is 48h; the concentration of added NaOH is 0.5M, the termination pH=8; the molecular weight cutoff of the dialysis bag is 14kDa.

[0019] S7 substrate amination: the purified A3 sample was transferred to a light-shielded reactor, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were added to activate the carboxyl group of A3, and then 1 M ethylenediamine was added to carry out amination reaction. After the reaction was completed, water was dialyzed with a dialysis bag until the conductivity was constant to obtain a purified aminated sample A4;

[0020] Preferably, the activation conditions of S4 are: CNC-II concentration 1wt.%, CNC-II: EDC: NHS absolute dry weight ratio 1: 0.24: 0.03, the pH of the reaction system is adjusted to 3.5, the amount of ethylenediamine is 10mL, and the reaction time is 5h;

[0021] S8 thermosensitive reagent carboxylation: maleic anhydride is used to react with the terminal hydroxyl groups of the thermosensitive polymer to obtain the carboxylated sample A5;

[0022] Preferably, the thermosensitive polymer in S8 is F124, the reaction is carried out at 170°C, with nitrogen as the protective gas, an appropriate amount of pyridine as the catalyst, and the reaction time is 6h;

[0023] S9 grafting: The purified A4 sample was transferred to a light-shielded reactor, EDC and NHS were added, and then 1MA5 was added for amidation reaction. After the reaction, water was dialyzed using a dialysis bag until the conductivity was constant to obtain the graft product A6 of A5 on A4;

[0024] Preferably, the reaction conditions of S9 are: CNC-II concentration 1wt.%, CNC-II:EDC:NHS absolute dry weight ratio 1:0.24:0.03, pH of the reaction system adjusted to 3.5, A5 polymer dosage 10mL, reaction time 24h;

[0025] Construction of S10 temperature-responsive Pickering emulsion: A6 aqueous solution is used as the water phase and then mixed with the oil phase. A6 is used as a Pickering emulsifier to form a stable Pickering emulsion. The emulsion is temperature-responsive. The emulsion is stable at 37°C and gradually demulsifies when the temperature rises. It completely demulsifies when the temperature reaches 40°C, thus constructing a temperature-responsive emulsion system.

[0026] 2. Application of temperature-responsive drug release system in ibuprofen antipyretic drug

[0027] Ibuprofen is a common non-steroidal anti-inflammatory drug. Ibuprofen is first dissolved in a n-hexane oil phase and then mixed with the two phases of the A6 aqueous solution in the S10 as the water phase. A6 acts as a Pickering emulsifier to form a stable Pickering emulsion, which has the characteristics of temperature-controlled release. Preferably, the concentration of A6 in the water phase is 0.8wt.%, the concentration of ibuprofen in the oil phase is 5mg / mL, and the volume ratio of the oil phase to the water phase of the emulsion is 3:7.

[0028] Beneficial effects:

[0029] Compared with the prior art, the grafting method provided by the present invention has the following advantages:

[0030] ● High responsiveness: The method of the present invention achieves a rapid response to temperature changes by using cellulose II nanocrystals (CNC-II) as a substrate and through specific chemical modifications. The reducing end groups of CNC-II are successfully grafted with a temperature-responsive polymer F124, which enables the system to rapidly change its physical state at a specific temperature, resulting in a change in the stability of the Pickering emulsion, thereby controlling the release of the drug.

[0031] ● Suitable for the human body: The transition temperature of the patented thermosensitive drug controlled-release system is just slightly higher than the normal human body temperature of 37-40°C, which is very suitable for situations where the body temperature rises due to illness, and can increase the release rate of the drug; however, the transition temperature of F124 itself is 45-50°C, which is not suitable for temperature-controlled sustained release in the human body.

[0032] ●Precise drug control: Compared with traditional drug release systems, the present invention can accurately regulate the drug release rate according to slight changes in ambient temperature, achieve precise control of drug concentration, improve treatment effects and reduce potential side effects.

[0033] ● Biocompatibility and biodegradability: CNC-II, as a natural material, has good biocompatibility and biodegradability, making the drug release system of the present invention safer in biomedical applications and reducing the risks that may be caused by long-term implantation.

[0034] ●Wide application: The drug release system of the present invention is not limited to the treatment of one drug or disease. Its temperature responsiveness makes it have potential application value in the treatment of various diseases, including but not limited to cancer treatment, infectious diseases, chronic disease management, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 : Reaction mechanism diagram of cellulose II nanocrystals grafted with thermosensitive reagent.

[0036] Figure 2 : Photos of temperature response behavior of CF4-II and F124 (1wt.%).

[0037] Figure 3 :(a) XRD patterns of CNC-II, Ox-CNC-II and CF4-II; (b) XPS scanning full spectra of CNC-II and CF4-II; (c) C1s fine spectra of CNC-II and CF4-II; (d) Changes in hydrated particle size of CNC-II and CF4-II at different temperatures.

[0038] Figure 4:(a) Storage stability of Pickering emulsion stabilized by CNC-II and CF4-II; (b) Microscope photos of CNC-II and CF4-II emulsions.

[0039] Figure 5 : Droplet diameter of Pickering emulsion (a) CNC-II, (b) CF4-II; modulus scan of Pickering emulsion (c) CNC-II, (d) CF4-II.

[0040] Figure 6 :(a) Changes of the complex shear viscosity of Pickering emulsions with different oil phases stabilized by CNC-II and CF4-II with temperature;(b) Changes of the complex shear viscosity of n-hexane Pickering emulsion stabilized by CF4-II with temperature;(c) Changes of droplet size and droplet polydispersity coefficient of n-hexane Pickering emulsion stabilized by CF4-II at different temperatures;(d) CF4-II stabilized Pickering emulsion controls the release of ibuprofen and compares it with CNC-II. DETAILED DESCRIPTION

[0041] The purpose of the present invention is to provide a temperature-responsive drug release system constructed using cellulose II nanocrystals (CNC-II). The system can control the release of drugs at a specific temperature and is suitable for a variety of drug delivery scenarios. The following steps describe the implementation of the present invention:

[0042] 1. Preparation of CNC-II: First, cellulose is mercerized to transform its crystal form, and then microcrystalline cellulose is hydrolyzed with sulfuric acid to prepare nanocellulose crystals (CNC-II) with cellulose II crystal form. The acid concentration, temperature and time are controlled to obtain CNC-II of the desired size and morphology.

[0043] 2. End group modification of CNC-II: Use NaClO2 system to oxidize the end groups of CNC-II and introduce carboxyl functional groups to prepare for the subsequent grafting reaction.

[0044] 3. Amination reaction: The oxidized CNC-II was mixed with N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (NHS), and then ethylenediamine was added to carry out an amination reaction.

[0045] 4. Carboxylation of thermosensitive materials: Maleic anhydride is used to react with the terminal hydroxyl groups of a thermosensitive polymer (such as F124) to obtain a carboxyl-modified thermosensitive polymer.

[0046] 5. Polymer grafting: The aminated CNC-II is mixed with a carboxylated modified polymer (such as F124) and a grafting reaction is carried out at room temperature to form a temperature-responsive CNC-II.

[0047] 6. Drug loading: dissolve the drug (such as ibuprofen) in the oil phase.

[0048] 7. Preparation of Pickering emulsion: The grafted CNC-II was mixed with the oil phase and the water phase, and the Pickering emulsion was prepared by emulsification and ultrasonic treatment. The drug was encapsulated in the emulsion through the emulsion preparation process.

[0049] 8. Temperature-responsive release: At a specific temperature, the thermosensitive polymer grafted on the surface of CNC-II undergoes a phase change, causing the emulsion to rupture, achieving controlled release of the drug.

[0050] The present invention is further described in detail below in conjunction with implementation examples, but the implementation methods of the present invention are not limited thereto.

[0051] Example

[0052] At room temperature, 30 g of microcrystalline cellulose was added to 525 mL of 17.5 wt.% NaOH solution (solid / liquid ratio of 1:17.5) and soaked for 24 hours to ensure complete conversion of cellulose. The alkaline solution was then removed by decanting the supernatant and vacuum filtration until the pH of the suspension was neutral. The mercerized microcrystalline cellulose was then freeze-dried for subsequent use. The treated sample was called MCC-II.

[0053] First, the freeze-dried MCC-II was ground into fine powder. Then, 10 g of MCC-II was added to a 500 mL three-necked round-bottom flask, and 100 mL of sulfuric acid of a specific concentration was added and preheated to the designed temperature in advance (see Table 2-4 for details). The hydrolysis process was carried out under stirring conditions of 500 rpm per minute. After reaching the designed reaction time, 10 times of water was added to stop the hydrolysis reaction. The diluted suspension was centrifuged at room temperature (10000 rpm) for 15 min, and the supernatant was decanted. Repeat the centrifugation 3 times to remove the residual acid. Then, deionized water was dialyzed using a cellulose acetate membrane (molecular weight cutoff of 14 KDa) until the pH value of the suspension was neutral. The CNC suspension was then rotary evaporated to a certain concentration and then stored at 4°C for subsequent use.

[0054] MCC II was hydrolyzed to prepare CNC-II, and the specific conditions used were acid concentration 64%, temperature 45°C, and time 15 min. The hydrolyzed and dialyzed CNC was homogenized 20 times at a concentration of 0.1wt.% using a high-pressure homogenizer (UH-20, China Yonglian Biotechnology) at a pressure of 400 bar to obtain a relatively uniform CNC-II. Subsequently, the homogenized CNC-II suspension was rotary evaporated to a specific concentration for subsequent use.

[0055] Oxidation method of reducing end groups of CNC-II. First, take a CNC-II suspension with a concentration of about 1% and an absolute dry CNC-II content of 1g in a light-shielded reaction bottle, add 3.78g NaClO2, then add HAc to adjust the pH to 3.5, and stir for 48h. After the reaction time is reached, add 0.5M NaOH solution to adjust the system pH to pH = 8 to stop the reaction, transfer to a 14kDa dialysis bag, and then dialyze against water until the conductivity is constant. The oxidized sample is called Ox-CNC-II.

[0056] The purified Ox-CNC-II sample was transferred to a light-shielded reaction bottle, and 0.24 g EDC and 0.03 g NHS were added, followed by 10 mL of 1 M ethylenediamine, and then reacted at room temperature for 5 h. After the reaction, water was dialyzed using a 14 kDa dialysis bag until the conductivity was constant. The aminated sample was called An-CNC-II.

[0057] Maleic anhydride was used to react with the terminal hydroxyl group of the thermosensitive polymer (F124). The reaction was carried out at 170° C. with nitrogen as the protective gas and an appropriate amount of pyridine as the catalyst. The reaction was carried out for 6 hours to finally obtain carboxylated F124.

[0058] The aminated An-CNC-II sample was transferred to a light-shielded reaction bottle, 0.24 g EDC and 0.03 g NHS were added, followed by 10 mL of 1 M carboxylated modified polymer (such as carboxylated F124), and then reacted at room temperature for 24 h. After the reaction, water was dialyzed using a 2 kDa dialysis bag until the conductivity was constant. Finally, a temperature-responsive material with F124 grafted at the end of CNC-II was obtained, called CF4-II.

[0059] CNC-II, CF4-II samples (0.8wt.%) and oil phase (n-hexane) were added to a screw-capped penicillin bottle in an oil-water ratio of 3:7. The mixture was first emulsified at 14000rpm for 1min using an emulsifier, and then ultrasonic cell disruptor was used to ultrasonicate for 3min (on for 2s, off for 2s) at 300W power to prepare a uniform emulsion, and the emulsion stability was tested.

[0060] In the process of preparing the emulsion, ibuprofen was first dissolved in n-hexane of the oil phase at a concentration of 5 mg / ml, and a CF4-II sample (0.8 wt.%) was used as the aqueous phase to prepare a Pickering emulsion with an oil-water ratio of 3:7 to obtain a temperature-controlled release system of ibuprofen. Then, 1 mL of the CF4-II-stabilized Pickering emulsion sample was taken and transferred to a dialysis bag with a molecular weight cutoff of 8000 to 14000 Da, followed by adding 1 mL of PBS buffer at pH = 7.4, and the dialysis bag was clamped and transferred to a small beaker containing 8 mL of PBS buffer. The beaker containing the emulsion and PBS buffer was transferred to a shaker at 37°C and 150 rpm for 2 hours, and 1 mL of PBS buffer in the beaker was taken out every 30 minutes and 1 mL of fresh PBS buffer was added at the same time. The concentration of ibuprofen released was determined by measuring the absorbance of the buffer at 273 nm. After keeping warm for 2 hours, the temperature was raised to 40°C and samples were taken every 30 minutes. After 2 hours, samples were taken every hour and the sampling was continued for 8 hours.

[0061] The reaction diagram is attached. Figure 1 The reaction products are shown in the attached Figure 2 , its TEM image is shown in Figure 3 The difference between the emulsification effect and the control example is shown in the following line. Figure 4 The droplet diameter of the Pickering emulsion is Figure 5 (a), the modulus scan of the emulsion is shown in Figure 5 (b), the properties of the emulsion change with temperature and the controlled release of the model drug ibuprofen Figure 6 Compared with the control example, the controlled release temperature of the embodiment is just between 37 and 40°C, which matches the normal temperature and abnormal temperature (such as fever) of the human body. Figure 6 (d).

[0062] Comparative Example 1

[0063] The control example uses CNC-II, which has not undergone the reducing end oxidation, amination, grafting and other reactions described in the examples. Its XRD and XPS analysis is shown in the attached Figure 3 The controlled release effect of ibuprofen is shown in Figure 6 (d) As can be seen from the figure, CNC-II alone has no temperature-controlled release effect.

[0064] Comparative Example 2

[0065] The control example uses F124 without grafting with CNC-II. Its response temperature is between 45 and 50°C (see Figure 2 ), does not have the temperature controlled release function between 37 and 40°C.

[0066] The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention. Any figure mark in the claims should not be regarded as limiting the claims involved.

[0067] In addition, it should be understood that although the present specification is described according to implementation modes, not every implementation mode contains only one independent technical solution. This description of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment may also be appropriately combined to form other implementation modes that can be understood by those skilled in the art.

Claims

1. A method for constructing a temperature-responsive drug release system, characterized in that The method comprises the following steps: S1 raw material: microcrystalline cellulose, cotton linters, bleached pulp and other cellulose raw materials are used as the base material, and a thermosensitive polymer is used as the modification auxiliary agent; preferably, the cellulose raw material of S1 is microcrystalline cellulose, and the S1 thermosensitive modification agent is commercial polyether F124 (CAS: 9003-11-6), which is a block copolymer of propylene oxide and ethylene oxide, with a molecular weight Mn of 2090-2360; S2 crystal conversion. 17.5wt.% NaOH solution is added to the microcrystalline cellulose to ensure complete conversion of the cellulose, and then the alkaline solution is removed by decanting the supernatant and vacuum filtration until the pH value of the suspension is neutral, and finally the mercerized cellulose raw material A1 is freeze-dried for subsequent use; preferably, the solid / liquid weight ratio of S2 is 1:20 and soaked for 24 hours to ensure complete conversion of the cellulose; Preparation of S3 cellulose II nanocrystals (CNC-II): hydrolyze A1 in S2 in a 64% (w / v) H2SO4 solution, then centrifuge to remove the acid solution, and use dialysis to remove residual acid from the centrifuged cellulose nanocrystals; preferably, the solid / liquid weight ratio of the S3 hydrolysis is 1:100, the temperature is 45°C, and the time is 15 min; S4 high-pressure homogenization: The hydrolyzed and dialyzed cellulose nanocrystals are treated with a high-pressure homogenizer to obtain relatively uniform cellulose II nanocrystals (CNC-II) A2; preferably, the concentration of the S4 high-pressure homogenization is 0.1wt.%, the pressure is 400bar, and the number of homogenizations is 15-20 times; S5 concentration: Subsequently, the homogenized A2 suspension is rotary evaporated to a specific concentration for subsequent use; S6 Substrate end group oxidation: NaClO2 was added to the CNC-II suspension described in S5, and acetic acid was added dropwise to adjust the pH. The oxidation reaction was carried out under continuous stirring. After the reaction time was reached, an alkali solution was added to terminate the reaction. The sample was transferred to a dialysis bag and dialyzed against water until the conductivity was constant to obtain a purified reducing end oxidation sample A3: Preferably, the reaction conditions of S6 are: CNC-II concentration 1wt.%, and CNC-II:NaClO2 weight ratio 1:3.78; the pH of the reaction system is adjusted to 3.5, the reaction time is 48h; the concentration of added NaOH is 0.5M, the termination pH=8; the molecular weight cutoff of the dialysis bag is 14kDa. S7 substrate amination: the purified A3 sample was transferred to a light-shielded reactor, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were added to activate the carboxyl group of A3, and then 1 M ethylenediamine was added to carry out amination reaction. After the reaction was completed, water was dialyzed with a dialysis bag until the conductivity was constant to obtain a purified aminated sample A4; Preferably, the activation conditions of S4 are: CNC-II concentration 1wt.%, CNC-II: EDC: NHS absolute dry weight ratio 1: 0.24: 0.03, the pH of the reaction system is adjusted to 3.5, the amount of ethylenediamine is 10mL, and the reaction time is 5h; S8 thermosensitive reagent carboxylation: maleic anhydride is used to react with the terminal hydroxyl groups of the thermosensitive polymer to obtain the carboxylated sample A5; Preferably, the thermosensitive polymer in S8 is F124, the reaction is carried out at 170°C, nitrogen is used as the protective gas, an appropriate amount of pyridine is used as the catalyst, and the reaction is carried out for 6 hours; S9 grafting: The purified A4 sample was transferred to a light-shielded reactor, EDC and NHS were added, and then 1 M A5 was added for amidation reaction. After the reaction, water was dialyzed using a dialysis bag until the conductivity was constant to obtain the graft product A6 of A5 on A4; Preferably, the reaction conditions of S9 are: CNC-II concentration 1wt.%, CNC-II:EDC:NHS absolute dry weight ratio 1:0.24:0.03, pH of the reaction system adjusted to 3.5, A5 polymer dosage 10mL, reaction time 24h; Construction of S10 temperature-responsive Pickering emulsion: A6 aqueous solution is used as the water phase and then mixed with the oil phase. A6 is used as a Pickering emulsifier to form a stable Pickering emulsion. The emulsion is temperature-responsive. The emulsion is stable at 37°C and gradually demulsifies when the temperature rises. It completely demulsifies when the temperature reaches 40°C, thus constructing a temperature-responsive emulsion system.

2. Application of temperature-responsive drug release system in ibuprofen antipyretic drug Ibuprofen is a common non-steroidal anti-inflammatory drug. Ibuprofen is first dissolved in a n-hexane oil phase and then mixed with the two phases of the A6 aqueous solution in the S10 as the water phase. A6 acts as a Pickering emulsifier to form a stable Pickering emulsion, which has the characteristics of temperature-controlled release. Preferably, the concentration of A6 in the water phase is 0.8wt.%, the concentration of ibuprofen in the oil phase is 5mg / mL, and the volume ratio of the oil phase to the water phase of the emulsion is 3:7.

Citation Information

Cited By

  • Polyethylene and silica gel mixed material, preparation method and composite optical cable silicon core tube

    CN120795443A

  • Temperature-responsive Pickering emulsion and preparation method thereof

    CN121343246A